Moneycontrol PRO
you are here: HomeNewsAstrazeneca
astrazeneca
Jump to
  • AstraZeneca India gets approval to market anti-diabetes drug Nov 29, 2022 02:15 PM IST

    AstraZeneca India gets approval to market anti-diabetes drug

    Dapagliflozin is the first and only anti-diabetic drug approved to significantly reduce the risk of sustained eGFR (estimated Glomerular Filtration Rate), cardiovascular deaths and hospitalisations due to heart failure in adults with progressive chronic kidney disease, the drug firm said.

  • AstraZeneca Standalone September 2022 Net Sales at Rs 236.13 crore, up 19.43% Y-o-Y Nov 15, 2022 03:33 PM IST

    AstraZeneca Standalone September 2022 Net Sales at Rs 236.13 crore, up 19.43% Y-o-Y

  • AstraZeneca looks to more than double new cancer drugs by 2030 Sep 12, 2022 10:47 AM IST

    AstraZeneca looks to more than double new cancer drugs by 2030

    The UK drugmaker has added seven new cancer medicines since 2014, after Chief Executive Officer Pascal Soriot made a risky bet on an oncology pipeline to revive growth and ward off a hostile takeover from Pfizer Inc.

  • AstraZeneca may not stay in vaccines, but CEO has no COVID regrets Aug 24, 2022 07:06 AM IST

    AstraZeneca may not stay in vaccines, but CEO has no COVID regrets

    Production delays, probes by regulators following rare cases of severe side effects, and concerns about its relatively short shelf life compared with other shots have stymied adoption of the company's COVID-19 vaccine.

  • AstraZeneca India receives DCGI's nod to market drug treating breast cancer Aug 19, 2022 05:45 PM IST

    AstraZeneca India receives DCGI's nod to market drug treating breast cancer

    The Drugs Controller General of India (DCGI) has approved Lynparza (Olaparib) as a monotherapy for the treatment of adult patients with early breast cancer.

  • AstraZeneca Standalone June 2022 Net Sales at Rs 232.33 crore, up 32.46% Y-o-Y Aug 08, 2022 07:00 PM IST

    AstraZeneca Standalone June 2022 Net Sales at Rs 232.33 crore, up 32.46% Y-o-Y

  • AstraZeneca Standalone March 2022 Net Sales at Rs 231.96 crore, up 10.32% Y-o-Y May 27, 2022 04:12 PM IST

    AstraZeneca Standalone March 2022 Net Sales at Rs 231.96 crore, up 10.32% Y-o-Y

  • AstraZeneca's COVID jab Vaxzevria wins EU approval as booster May 23, 2022 02:30 PM IST

    AstraZeneca's COVID jab Vaxzevria wins EU approval as booster

    "Healthcare professionals can now use Vaxzevria as a third dose booster in patients previously given a primary vaccine schedule of either Vaxzevria or an EU-approved mRNA COVID-19 vaccine."

  • COVID vaccine maker AstraZeneca sees profit slump Apr 29, 2022 01:36 PM IST

    COVID vaccine maker AstraZeneca sees profit slump

    Profit after tax slumped to $386 million (366 million euros), AstraZeneca said in a statement.

  • World's biggest vaccine maker Serum halts production with 200 million doses spare Apr 23, 2022 09:03 AM IST

    World's biggest vaccine maker Serum halts production with 200 million doses spare

    The Serum Institute has produced more than one billion doses of Covishield -- its version of the AstraZeneca jab -- and is a major supplier to the Covax global inoculation programme for poorer countries.

  • Europe begins reviewing application for AstraZeneca COVID drug Mar 16, 2022 01:10 PM IST

    Europe begins reviewing application for AstraZeneca COVID drug

    Infections from COVID-19 are still rising in parts of the world including Europe.

  • COVID vaccine maker AstraZeneca says 2021 profit dives Feb 10, 2022 02:49 PM IST

    COVID vaccine maker AstraZeneca says 2021 profit dives

    Profit after tax slumped to just $112 million (98 million euros) compared with $3.2 billion in 2020, the pharmaceutical company said in a statement.

  • AstraZeneca Standalone December 2021 Net Sales at Rs 200.53 crore, up 0.14% Y-o-Y Feb 09, 2022 01:22 PM IST

    AstraZeneca Standalone December 2021 Net Sales at Rs 200.53 crore, up 0.14% Y-o-Y

  • AstraZeneca China summoned over suspected fraud Jan 30, 2022 07:52 AM IST

    AstraZeneca China summoned over suspected fraud

    The regulator of the state medical insurance fund said authorities ordered the arrest of all suspects, but did not give details of the suspected violations or the size of funds involved.

  • AstraZeneca says early trial data indicates third dose helps against Omicron Jan 13, 2022 03:37 PM IST

    AstraZeneca says early trial data indicates third dose helps against Omicron

    The increased response, also against the Delta variant, was seen in a blood analysis of people who were previously vaccinated with either Vaxzevria or an mRNA vaccine, the drugmaker said, adding that it would submit this data to regulators worldwide given the urgent need for boosters.

  • What is marketing authorisation that Covishield has applied for? Jan 03, 2022 01:52 PM IST

    What is marketing authorisation that Covishield has applied for?

  • AstraZeneca vaccine booster shot effective against Omicron: Oxford lab study Dec 23, 2021 01:19 PM IST

    AstraZeneca vaccine booster shot effective against Omicron: Oxford lab study

    The study, yet to be published in a peer-reviewed medical journal, showed antibody levels against Omicron after the booster shot were higher than antibodies in people who had been infected with and recovered naturally from COVID-19.

  • AstraZeneca Covid vaccine protection wanes after three months: Lancet study Dec 21, 2021 05:24 PM IST

    AstraZeneca Covid vaccine protection wanes after three months: Lancet study

    The findings drawn from datasets in Brazil and Scotland suggest that booster programmes are needed to help maintain protection from severe disease in those vaccinated with AstraZeneca, known as Covishield in India.

  • USFDA study shows Evusheld retains neutralising activity against Omicron: AstraZeneca Dec 17, 2021 03:36 PM IST

    USFDA study shows Evusheld retains neutralising activity against Omicron: AstraZeneca

    The study was done independently by investigators at the US Food and Drug Administration (USFDA), Center for Biologics Evaluation and Research.

  • Pfizer set to oust AstraZeneca as top supplier of COVID-19 shots to poor nations Dec 15, 2021 11:53 AM IST

    Pfizer set to oust AstraZeneca as top supplier of COVID-19 shots to poor nations

    The expected change comes with headaches for receiving countries that lack sufficient cold storage capacity to handle the Pfizer vaccine, and amid risks of a shortage of syringes needed to administer that shot.

  • Trigger of rare blood clots linked with AstraZeneca Covid vaccine found Dec 02, 2021 08:04 PM IST

    Trigger of rare blood clots linked with AstraZeneca Covid vaccine found

    An international team of researchers investigated vaccine-induced immune thrombotic thrombocytopenia (VITT), also known as thrombosis with thrombocytopenia syndrome (TTS), a life-threatening condition seen in a very small number of people after receiving the adenovirus vaccines.

  • AstraZeneca says it will start profiting from its COVID-19 vaccine Nov 13, 2021 02:57 PM IST

    AstraZeneca says it will start profiting from its COVID-19 vaccine

    To a far greater extent than the vaccines from Pfizer-BioNTech and Moderna, AstraZeneca’s vaccine has been the workhorse of the effort to vaccinate poorer countries, many of which are facing severe vaccine shortages. About 1.1 billion AstraZeneca doses had reached low- and lower-middle income countries as of around the end of October

  • AstraZeneca Standalone September 2021 Net Sales at Rs 197.71 crore, down 5.62% Y-o-Y Nov 11, 2021 10:00 AM IST

    AstraZeneca Standalone September 2021 Net Sales at Rs 197.71 crore, down 5.62% Y-o-Y

  • Pfizer, AstraZeneca COVID vaccines generate more antibodies than natural infection: Study Nov 08, 2021 06:19 PM IST

    Pfizer, AstraZeneca COVID vaccines generate more antibodies than natural infection: Study

    A team led by researchers at the University of Montreal in Canada found that these antibodies were also effective against the Delta variant.

  • AstraZeneca sets up clinical data insights division in India Oct 20, 2021 02:43 PM IST

    AstraZeneca sets up clinical data insights division in India

    The Bengaluru-based clinical data and insights (CDI) division is a critical advancement to support a growing global portfolio and build on internal data expertise, the drug firm said in a statement.